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Abstract 
It has been hypothesized that interleukin-1 (IL-1) is released from damaged 
cardiomyocytes following myocardial infarction (MI) and activates cardiac fibroblasts via its 
receptor (IL-1R1) to drive the early stages of cardiac remodeling. This study aimed to 
definitively test this hypothesis using cell type-specific IL-1 and IL-1R1 knockout (KO) 
mouse models. A floxed Il1a mouse was created and used to generate a cardiomyocyte-
specific IL-1 KO mouse line (MIL1AKO). A tamoxifen-inducible fibroblast-specific IL-
1R1 hemizygous KO mouse line (FIL1R1KO) was also generated. Mice underwent 
experimental MI (permanent left anterior descending coronary artery ligation) and cardiac 
function was determined 4 weeks later by conductance pressure-volume catheter analysis. 
Molecular markers of remodeling were evaluated at various time points by real-time RT-PCR 
and histology. MIL1AKO mice showed no difference in cardiac function or molecular 
markers of remodeling post-MI compared with littermate controls. In contrast, FIL1R1KO 
mice showed improved cardiac function and reduced remodeling markers post-MI compared 
with littermate controls. In conclusion, these data highlight a key role for the IL-1R1/cardiac 
fibroblast signaling axis in regulating post-MI remodeling and provide support for the 
continued development of anti-IL-1 therapies for improving cardiac function after MI. 
Cardiomyocyte-derived IL-1 was not an important contributor to post-MI remodeling in this 
model. 
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Introduction 
Although widely recognized as key regulators of extracellular matrix (ECM) turnover, 
cardiac fibroblasts also have wide-reaching functions that are fundamental to the overall 
physiology and pathophysiology of the heart, including sensing tissue damage and 
contributing to cardiac inflammation (1,2). Cardiac fibroblasts are particularly responsive to 
the proinflammatory cytokine interleukin (IL)-1 (3), whose levels are increased with many 
cardiovascular pathologies including myocardial infarction (MI), cardiomyopathy, 
myocarditis and hypertension (4,5). In response to IL-1 stimulation, cardiac fibroblasts 
secrete an array of proinflammatory cytokines and chemokines, and enhance ECM turnover 
through increased secretion of matrix metalloproteinases (MMPs), decreased collagen 
synthesis and decreased expression of profibrotic cytokines (3). Thus, fibroblasts can 
contribute to the inflammatory milieu that occurs in the myocardium early after MI, and the 
IL-1/cardiac fibroblast signaling axis is a potentially important mediator of post-MI cardiac 
remodeling (2,3). Furthermore, there is growing evidence to suggest that IL-1 blockade is a 
viable therapeutic strategy for treating cardiovascular disease (6-8).  
IL-1 comprises two distinct gene products (IL-1 and IL-1β) that have generally 
indistinguishable biological activities and play a significant role in the pathogenesis of heart 
disease (4). Despite their similarity of action, IL-1 and IL-1β are produced by cells through 
very different mechanisms. IL-1 is an intracellular cytokine (nuclear and cytosolic) that is 
released when cells undergo necrosis and was originally shown to be a key trigger for 
inflammation in the liver (9). Importantly, it has also been proposed that IL-1 release from 
necrotic cardiomyocytes acts in a similar manner, triggering the early inflammatory response 
after MI (10). This key role for IL-1 in post-MI inflammation has been supported by a 
recent murine study in which an IL-1-specific blocking antibody reduced myocardial injury 
and improved cardiac function after experimental MI (11). In contrast to IL-1, IL-1β is 
inactive until it undergoes inflammasome-mediated proteolytic processing prior to non-
classical secretion from cells in response to specific stimuli (12). In mice, cardiomyocytes 
express both IL-1 and IL-1β, whereas cardiac fibroblasts express IL-1β, but not IL-1 (10). 
 Irrespective of their differences in expression, synthesis, activation and secretion, the 
biological effects of both IL-1 and IL-1β are mediated through the same receptor, 
interleukin-1 receptor-1 (IL-1R1). Ligand binding to IL-1R1 stimulates its association with 
the IL-1 receptor accessory protein (IL-1RacP) which in turn recruits the MyD88 and IRAK4 
signaling proteins to form a stable tetrameric signaling module in which all components are 
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essential (13). The downstream functional effects of IL-1 are mediated primarily via MAP 
kinase (ERK, p38, JNK) and NF-B signaling pathways which are stimulated following 
recruitment of further adaptor proteins and kinases to the core IL-1R1 signaling module 
(3,13). 
 Studies on IL-1R1 global knockout (KO) mice have revealed a critical role for IL-1R1 
in mediating cardiac myofibroblast accumulation, MMP expression and fibrotic remodeling 
of the infarcted heart (14-16). The beneficial effects observed in IL-1R1 KO mice were 
largely the result of suppressed inflammation, however direct effects on cardiac fibroblasts 
were also suggested (14). Nevertheless, the global nature of these IL-1R1 KO models makes 
it difficult to evaluate the precise contribution of IL-1 signaling in cardiac fibroblasts.  
 Taken together, these in vivo and in vitro studies suggest that interplay between IL-1 
(released from damaged cardiomyocytes) and IL-1R1 activation (on cardiac fibroblasts) is 
critical in the early myocardial remodeling process after MI. However, to date no studies 
have sought to directly evaluate the importance of these interactions in vivo in a cell-specific 
context. The aim of this study was to use cell type-specific KO mouse models to investigate 
the role of cardiomyocyte IL-1 and fibroblast IL-1R1 in regulating post-MI cardiac 
remodeling. 
 
 
Results 
Cardiomyocyte-specific IL-1 knockout does not affect cardiac function or remodeling 
after experimental MI 
A cardiomyocyte-specific IL-1 KO mouse model was generated to evaluate the contribution 
of cardiomyocyte-derived IL-1 to cardiac remodeling after MI. Firstly, a floxed Il1a mouse 
was created in which exon 4 of the Il1a gene was modified to be flanked by loxP sites 
(Figure 1A, Supplemental Figure 1A). Floxed Il1a mice were then bred with mice 
expressing Cre recombinase under control of the cardiomyocyte-specific Myh6 promoter to 
produce Cre-positive cardiac myocyte-specific IL-1 KO (MIL1AKO) mice and control Cre-
negative floxed littermates (Supplemental Figure 1B). Deletion PCR confirmed that Cre-
positive MIL1AKO mice had the expected deletion within exon 4 of the Il1a gene, and that 
this was only apparent in heart tissue (Figure 1B). Mean Il1a mRNA expression levels in 
whole heart samples from control mice were relatively low and were further reduced in hearts 
from MIL1AKO mice (Figure 1D), reflecting Il1a gene deletion in the cardiomyocyte 
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population of the heart. Baseline cardiac characteristics in control (Cre-negative Il1afl/fl) and 
MIL1AKO (Cre-positive Il1afl/fl) mice were assessed by pressure-volume (P-V) conductance 
catheter analysis and showed no difference between groups (Supplemental Figure 2A). 
Basal expression levels of remodeling genes (collagens and hypertrophy markers) were also 
similar for the two lines (Supplemental Figure 2B). Thus, Cre-induced deletion of IL-1 in 
cardiomyocytes had no effect on the baseline cardiac phenotype of the animals.    
 To determine the impact of cardiomyocyte-specific IL-1 KO on post-MI function and 
remodeling, we used a permanent left anterior descending (LAD) coronary artery ligation 
model of experimental MI. Male Cre-negative (control) and Cre-positive (MIL1AKO) 
littermates underwent LAD ligation at 10-12 weeks of age (Figure 1C) and cardiac 
physiological measurements were obtained 4 weeks later by P-V conductance catheter 
analysis (Figure 1E). MI scarring was clearly visible in hearts obtained from animals that 
had undergone LAD ligation (Figure 2A).  
 As expected, control mice displayed overt cardiac dysfunction 4 weeks after MI, as 
evidenced by reduced ejection fraction (EF), increased end systolic volume (ESV) and 
increased end diastolic volume (EDV) compared to sham animals (Figure 1E), with other 
parameters being unaffected (Supplemental Table 1). Importantly, no difference in post-MI 
cardiac function was observed between control mice and MIL1AKO mice (Figure 1E, 
Supplemental Table 1), indicating that cardiomyocyte-derived IL-1 per se was not an 
important contributor to cardiac dysfunction after MI. 
 Assessment of gene expression in the infarct region 3 days after MI by real-time 
quantitative reverse transcription PCR (qRT-PCR) revealed increases in mRNA levels of 
inflammatory genes (Il1b, Tnfa, Il6) and ECM regulatory genes (Mmp3, Mmp9, Tnc, Postn, 
Col1a1, Col3a1), and reduced mRNA for the myofibroblast differentiation marker Acta2 in 
MI hearts compared to sham hearts (Figure 1F). Importantly, there was no difference in 
expression levels of these genes between control and MIL1AKO mice after MI (Figure 1F). 
Histological analysis of hearts 4 weeks after MI revealed no obvious differences between 
control and MIL1AKO mice, with both showing thinning of the LV free wall in the infarct 
area and scar tissue marked by ECM deposition (Figure 2B), in agreement with the 
functional and mRNA expression data.  
 
Characterization of fibroblast-specific IL-1R1 knockout mouse model 
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Having ruled out a role for cardiomyocyte-derived IL-1 in modulating cardiac remodeling 
after MI, we proceeded to investigate the specific role of the IL-1 receptor (IL-1R1) 
expressed by cardiac fibroblasts. Col1a2-CreER(T) mice have previously been used to induce 
Cre-lox-mediated deletion of genes specifically in fibroblasts (17), including those in the 
heart (18-20), without affecting cardiomyocytes, endothelial cells, smooth muscle cells, 
progenitor cells, pericytes or macrophages. We firstly developed a Col1a2-Cre-Il1r1fl/fl 
mouse line (see Supplemental Figure 3A for breeding strategy) to explore the effects of 
fibroblast-specific IL1R1 deletion on cardiac remodeling. However, this method was 
ineffective at reducing IL1R1 expression or activation in cardiac fibroblasts (data not shown), 
despite our previous success with this approach for deleting other genes (20). To overcome 
this problem we adopted a modified strategy to generate a hemizygous mouse line with 
global deletion of one Il1r1 allele in which the remaining allele was floxed. This approach is 
particularly useful for targeting genes whose heterozygous (+/-) KO does not cause a 
phenotype as it maximizes the impact of inducible KO of the remaining allele (21).    
 Therefore we first generated global IL-1R1+/- heterozygous mice and IL-1R1-/- KO 
mice (see Supplemental Figure 3B for breeding strategy) to investigate the phenotypic 
effect of mono-allelic and bi-allelic deletion of Il1r1. As expected, primary cultures of 
cardiac fibroblasts from heterozygous animals exhibited a 50% reduction in Il1r1 mRNA 
levels compared with wild type mice, with no detectable expression in those from IL-1R1 KO 
mice (Figure 3A). The functional impact of fibroblast IL1R1 KO was evaluated in cultured 
cardiac fibroblasts by measuring IL-1 responses; specifically kinase signaling pathways, 
gene expression and protein secretion. IL-1 stimulated the p38 and NF-κB signaling 
pathways (Figure 3B) and increased Il6, Mmp3 and Mmp9 mRNA expression (Figure 3C) 
and IL-6 and MMP-3 protein secretion (Figure 3D) to a similar extent in fibroblasts from 
wild-type and heterozygous mice, despite the latter expressing only half the amount of IL-
1R1. Cardiac fibroblasts from IL-1R1 KO mice did not respond to IL-1 stimulation (Figure 
3B-D), confirming full loss of the receptor. Responses to TNF, a proinflammatory cytokine 
that activates similar signaling pathways and gene expression profiles to IL-1 but via a 
different receptor, were unaffected in cardiac fibroblasts from IL-1R1 KO mice (Figure 
3B,E). Together, these data establish that full biallelic deletion of Il1r1 is necessary to disrupt 
IL-1 responses in cardiac fibroblasts and that mono-allelic deletion is ineffective. 
 We next generated hemizygous mice in which one Il1r1 allele was floxed and the other 
was deleted (fl/-). These animals were crossed with heterozygous mice that expressed 
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tamoxifen-inducible Cre recombinase (CreER(T)) under the control of the fibroblast-specific 
Col1a2 promoter (Figure 4A) to generate Col1a2-CreER(T)-Il1r1fl/- mice; a line we named 
FIL1R1KO (see Supplemental Figure 3C for breeding strategy). Example genotyping 
results are shown in Supplemental Figure 4. Mice were injected with tamoxifen at 12 days 
of age to induce Cre-loxP-mediated deletion, and hearts isolated after a further 4-8 weeks for 
analysis. The efficiency of fibroblast-specific deletion of IL-1R1 was confirmed in primary 
cultures of cardiac fibroblasts by qRT-PCR. Cells from FIL1R1KO mice had a mean 75% 
reduction in basal Il1r1 mRNA levels compared with cells from Cre-negative Il1r1fl/- 
littermate control mice (Figure 4B), indicating that full biallelic deletion of Il1r1 had 
occurred in response to tamoxifen in ~75% of cardiac fibroblasts. The functional impact of 
IL-1R1 deletion was evidenced by a marked reduction in the activation of the p38 and NF-κB 
signaling pathways in response to IL-1, without affecting TNF-induced signaling (Figure 
4C). Moreover, mean IL-1-induced Il6, Mmp3 and Mmp9 mRNA expression was reduced 
by 65-75% in fibroblasts cultured from FIL1R1KO hearts compared with cells from control 
littermate hearts (Figure 4D); in close agreement with the extent of IL1R1 knockdown 
(Figure 4B). Similar changes were noted for protein secretion; for example mean IL-1-
induced IL-6 secretion was reduced by >50% in cardiac fibroblasts from FIL1R1KO mice 
(Figure 4E).   
 
Fibroblast-specific IL-1R1 knockout improves cardiac remodeling after experimental MI 
Having confirmed functional and sustained knockdown of IL-1R1 in cardiac fibroblasts 
isolated from tamoxifen-treated FIL1R1KO mice, we next investigated the in vivo impact of 
fibroblast-selective IL-1R1 deletion on cardiac function after experimental MI (Figure 5A). 
Male Cre-negative (control) and Cre-positive (FIL1R1KO) littermates were injected with 
tamoxifen at 12 days of age for 5 consecutive days and underwent permanent LAD coronary 
artery ligation surgery at 10-12 weeks of age. Sham control animals (pooled Cre-negative and 
Cre-positive) were not injected with tamoxifen. There were no differences in baseline cardiac 
characteristics between Cre-positive and Cre-negative mice (Supplemental Figure 5). 
Physiological measurements were obtained 4 weeks after LAD ligation by P-V catheter 
analysis, before hearts were analyzed for histological and molecular markers of remodeling. 
P-V analysis (Figure 5B, Supplemental Table 2) revealed significantly reduced EF in 
control mice 4 weeks after MI compared with sham (48% versus 61% respectively; P=0.02), 
but importantly EF was only partially reduced to 56% in FIL1R1KO mice after MI and was 
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not significantly different to sham controls. dPdtmax (an indicator of contractility) was also 
significantly decreased in control MI mice compared with sham, but was less affected in 
FIL1R1KO mice, and not significantly different from sham animals. Similar, non-significant 
trends were observed with ESV and EDV (Figure 5B, Supplemental Table 2). End systolic 
pressures were significantly reduced in MI mice of both genotypes compared with sham 
animals whereas other cardiac parameters and arterial blood pressure were not significantly 
different between the three groups (Supplemental Table 2).  
 The impact of fibroblast-selective IL-1R1 deletion on specific molecular markers of 
cardiac remodeling was assessed by qRT-PCR of whole ventricle mRNA samples taken from 
hearts used for P-V analysis (i.e. 4 weeks after LAD ligation). Nine genes were studied that 
included markers of ECM synthesis (Col1a1, Col3a1), ECM degradation (Mmp3, Mmp9), 
myofibroblast activation (Acta2), mechanical activation (Tnc, Il6) and cardiomyocyte 
hypertrophy (Myh7, Nppa). Significant increases in Col1a1 (1.7-fold increase; P<0.05), 
Col3a1 (3.2-fold; P<0.001), Mmp3 (2.5-fold; P<0.05) and Tnc (2.1-fold; P<0.05) mRNA 
levels were observed in control post-MI hearts compared with sham hearts (Figure 5C). By 
comparison, the expression levels of all four of these genes was markedly less in post-MI 
hearts from FIL1R1KO mice [Col1a1 (1.3-fold increase), Col3a1 (1.8-fold; P<0.05 versus 
control MI), Mmp3 (1.7-fold), Tnc (1.3-fold)] and, with the exception of Col3a1, were not 
significantly different from sham levels (Figure 5C). 
 Histological staining was performed on hearts 5 days (Figure 6) or 6 weeks (Figure 7) 
after MI. In control mice, granulation tissue was evidenced after 5 days by inflammatory cell 
infiltration (Figure 6, H&E) and marked tenascin C expression (Figure 6), with a small 
amount of collagen expression (Figure 6, MVG). After 6 weeks, control mice had evidence 
of ventricular wall thinning (Figure 7) and more collagen deposition (Figure 7, MVG), with 
very little tenascin C expression (Figure 7). All these changes were more pronounced in 
control mice compared with FIL1R1KO mice (Figure 6 & 7).  
 
Discussion 
We used two novel cell-specific KO mouse models to investigate the role of cardiomyocyte-
derived IL-1 and the cardiac fibroblast IL-1 receptor, IL-1R1, in remodeling of the heart 
post-MI. The principal conclusion of our study was that fibroblast-specific deletion of IL-1R1 
was cardioprotective following MI, whereas cardiomyocyte-specific deletion of IL-1 had no 
effect. Our data with FIL1R1KO mice suggest that fibroblast IL-1R1 signaling is a significant 
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driver of detrimental cardiac remodeling post-MI. In vitro studies have revealed that cardiac 
fibroblasts adopt a pro-inflammatory, pro-angiogenic, pro-migratory, ECM-degrading, non-
differentiated phenotype in response to IL-1 [3]. Our in vivo observations suggest that these 
acute effects of IL-1 on cardiac fibroblasts early after MI contribute to longer-term adverse 
cardiac remodeling that is detrimental to cardiac function. These data support ongoing 
strategies aimed at inhibiting IL-1 or its receptor to improve cardiac function post-MI (6-8). 
 
Role of IL-1 
Cardiomyocyte-specific overexpression of human IL-1 induces cardiac hypertrophy in mice 
(22). Moreover, it has been proposed by Lugrin and colleagues that cardiomyocyte-derived 
IL-1 is important for stimulating the early inflammatory response post-MI (10). On the 
contrary, we observed no difference in cardiac function or expression of remodeling genes 
post-MI in a cardiomyocyte-specific IL-1 KO mouse (MIL1AKO) compared with control 
mice, suggesting that cardiomyocyte-derived IL-1 is not an essential player in this process. 
It is worth noting several differences between our study and that of Lugrin et al (10). Firstly, 
we used a cardiomyocyte-specific IL-1 KO mouse, whereas their study used global IL-1 
KO mice, so it is possible that the effects that were observed therein were due to IL-1 
deletion in non-myocyte cells (e.g. endothelial cells, fibroblasts, inflammatory cells), which 
together account for 70% of cells in the murine heart (23). Secondly, the experimental MI 
model used in that other study (10) was an ischemia-reperfusion model of MI as opposed to 
the permanent LAD ligation model we used. Although the ischemia-reperfusion model more 
closely resembles the clinical scenario where most patients undergo revascularization, the 
permanent occlusion model is particularly useful for understanding direct mechanisms 
without the confounding element of reperfusion. We chose the permanent occlusion model 
based on previous studies showing that interference of IL-1 signaling had favorable effects in 
both non-reperfusion (16) and reperfusion models (10,14). Finally, Lugrin et al (10), did not 
evaluate longer-term functional endpoints, with all measurements being taken immediately 
after the reperfusion period (2 hours). One of the markers studied was IL-6, whose increase 
was reduced in global IL-1 KO mice after the 2 h reperfusion period (10). In contrast, in our 
study, Il6 mRNA levels remained significantly elevated 3 days after permanent LAD 
occlusion and were not affected by cardiomyocyte-specific IL-1 deletion, indicating there 
was no long-term impact on inflammation. 
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Our results do not preclude an important role for IL-1 per se, and indeed there is 
recent evidence that cardiac IL-1 is important in post-MI cardiac remodeling, as 
administration of an IL-1 neutralizing antibody reduced infarct size and preserved LV 
systolic function in an ischemia-reperfusion model of MI (11). Although we observed that 
basal cardiac Il1a mRNA levels were very low, and were further reduced in MIL1AKO mice, 
IL-1 release can still occur in our model from non-myocyte cells, including endothelial 
cells, fibroblasts and macrophages; all of which may contribute to cardiac IL-1 levels after 
MI.  
 
Role of IL-1β 
Although our study did not directly investigate the contribution of IL-1β to post-MI 
remodeling, our data with the FIL1R1KO mouse may indicate a role for IL-1β acting on 
fibroblast IL-1R1. Indeed, such a role is supported by mouse and rat studies in which anti-IL-
1β neutralizing antibodies administered after MI improve cardiac function and limit adverse 
remodeling (24,25). IL-1β is produced by multiple cardiac cell types (26) and can directly 
promote adverse cardiac remodeling (4).  
 
Clinical relevance 
Therapeutic IL-1 blockade has now been evaluated in several cardiovascular clinical trials 
(reviewed in (6-8)). Initially, a number of small-scale trials investigated the effect of 
Anakinra, a recombinant form of the IL-1 receptor antagonist, on inflammation and cardiac 
remodeling in stable-STEMI and non-STEMI patients (27,28), reporting that IL-1 inhibition 
reduced post-MI inflammation, but had little effect on cardiac function in the longer term. 
This may relate to the relatively mild inflammatory phenotype in these patient cohorts 
compared with general STEMI patients, in whom IL-1 blockade was more effective (29). A 
more recent Anakinra trial (D-HART2) reported that IL-1 blockade did not improve 
cardiorespiratory fitness in obese HF patients with preserved ejection fraction, although 
markers of systemic inflammation and myocardial strain were reduced (30). In comparison to 
general IL-1 blockade with Anakinra, the recent CANTOS trial used an IL-1β-specific 
neutralizing antibody (Canakinumab) and reported a reduction in cardiovascular events 
independent of lipid levels (31), with a suggestion that the cardioprotective effects extended 
beyond new atherothrombotic events. Thus, there is gathering momentum for the use of 
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targeted anti-IL-1 therapies for improving outcome after MI, at least in some patient 
populations.  
 
Study limitations 
Although our study provided evidence for a role of fibroblast IL-1R1 in driving adverse 
cardiac remodeling, it remains unclear whether IL-1 or IL-1β (or both) is the most important 
stimulus. Our results with MIL1AKO mice ruled out a role for cardiomyocyte-derived IL-1, 
but other cellular sources of IL-1 were not explored. Future studies investigating selective 
IL-1 KO in other cardiac cell types (fibroblasts, endothelial cells, macrophages) will be 
required to explore this further. Similarly, global or cell-specific IL-1β KO mice would be 
helpful in determining the precise role of IL-1β in this setting. We used a permanent LAD 
ligation model of MI; investigations with an ischemia-reperfusion model of MI would be 
important to confirm our data in a more clinically appropriate model. We did not evaluate the 
area at risk in our MI models; although this might have been useful to understand the 
underlying mechanisms for cardioprotection in FIL1R1KO mice. Although we studied 
specific features of remodeling by quantifying expression levels of specific genes, and 
provided representative histological images, a more in-depth quantitative analysis of 
inflammation and fibrosis using supportive methodologies (e.g. flow cytometry and 
hydroxyproline incorporation respectively) would have strengthened our conclusions. 
Prolonged cardiomyocyte-specific Cre expression has been reported to result in modest 
cardiac dysfunction, fibrosis and hypertrophy in 6 month old Myh6-Cre mice (32), but not in 
3 month old mice (32,33). The MIL1AKO mice used in the current study were 10-12 weeks 
of age at the time of surgery and, although not directly addressed in our study, it is therefore 
unlikely that age-dependent Cre cardiotoxicity influenced the data.  
 
Conclusion 
Our data highlight the importance of the IL-1/cardiac fibroblast signaling axis in regulating 
post-MI remodeling and provide support for the continued development of anti-IL-1 therapies 
for improving cardiac function post-MI. 
 
Methods 
Animal welfare 
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Mice were maintained in individually ventilated cages at 21°C, 50-70% humidity, 12/12 h 
light/dark cycle with Pure-o’Cel paper bedding (Datesand) and ad libitum access to water and 
RM1 diet (Special Diets Services). 
 
Mouse models 
Floxed mice: Floxed Il1a (exon 4) mice were created as follows. Il1atm1a(EUCOMM)Wtsi 
embryonic stem cells (34) were purchased from the European Mouse Mutant Cell Repository 
(EuMMCR). Cells from clone EPD0822-4-H02 were prepared for microinjection according 
to the previously published protocol (35) with minor modifications. Briefly, cells were 
cultured in KO-DMEM + KOSR medium + 2i (MEK inhibitor and GSK3 inhibitor) on a 
gelatin-coated (0.1% gelatin in phosphate buffered saline) cell culture dish maintained under 
standard culture conditions (37°C, 5% CO2, humidified). Culture medium was changed daily 
and cells were passaged when 75-80% confluent using accutase to dissociate them. Cells 
were passaged no more than 3 times, and were transferred to media without 2i reagents for 24 
h prior to microinjection. Cells were then microinjected into 4 to 8 cell B6N-Tyrc-
Brd/BrdCrCrl embryos. Surviving embryos were surgically implanted into the oviduct of day 
0.5 post-coitum pseudopregnant mice. Resulting black/white C57BL/6N chimeras were back-
crossed onto C57BL/6N wild-type mice to assess germline penetrance. Potential founder 
mice were screened by PCR for LacZ, Neo and LoxP sites. This line was further crossed with 
C57BL/6N-Tg(CAG-Flpo)1Afst/Mmucd mice from the Mutant Mouse Resource & Research 
Centers (MMRRC). The FLP recombinase expression provided by this line resulted in a 
"conditional ready" (i.e. floxed) Il1atm1c(EUCOMM)Wtsi allele in which exon 4 is flanked by loxP 
sites. Floxed Il1r1 (exon 5) mice have been described previously (36) and were provided by 
Emmanuel Pinteaux (University of Manchester, UK).  
 
Cre-expressing mice: Cardiomyocyte-specific Myh6-Cre mice (011038) and PGK-Cre global 
deleter mice (020811) were obtained from The Jackson Laboratory (www.jax.org). 
Fibroblast-specific tamoxifen-inducible Col1a2-Cre-ER(T) mice have been well 
characterized (17,37) and were provided by Christopher Denton (University College London, 
UK).  
 
Breeding of cardiomyocyte-specific and fibroblast-specific KO mice: The breeding strategy to 
obtain cardiomyocyte-specific IL-1 KO mice (Supplemental Figure 1B) involved crossing 
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homozygous Il1afl/fl mice with heterozygous Myh6-Cre mice to generate Myh6-Cre-Il1afl/fl 
mice. When these were back-crossed with Il1afl/fl mice, Cre-positive cardiac myocyte-specific 
IL-1 KO mice (“MIL1AKO”) and Cre-negative floxed littermates (control) were produced.  
For investigating IL-1R1 in cardiac fibroblasts, a tamoxifen-inducible fibroblast-
specific IL-1R1 KO mouse line (Col1a2-CreER(T)-Il1r1fl/fl) was initially established on a 
C57BL/6 background by crossing Col1a2-CreER(T) mice with Il1r1fl/fl mice (Supplemental 
Figure 3A). Global IL-1R1 KO mice were subsequently established by crossing female 
PGK-Cre mice with male Il1r1fl/fl mice on a C57BL/6 background (Supplemental Figure 
3B). Finally, a tamoxifen-inducible fibroblast-specific IL-1R1 hemizygous KO mouse line 
“FIL1R1KO” (Col1a2-CreER(T)-Il1r1fl/-) was established by crossing heterozygous Col1a2-
Cre-ER(T) mice with Il1r1fl/fl mice on a C57BL/6 background (Supplemental Figure 3C). 
 
Tamoxifen-inducible Cre activation 
For the fibroblast-targeted studies, control (Cre-negative Il1r1fl/-) and FIL1R1KO mice were 
injected with tamoxifen dissolved in corn oil (100 mg/kg/day i.p. for 5 consecutive days) at 
12 days of age to induce CreER(T) activity and facilitate Cre/loxP-mediated deletion in Cre-
positive fibroblasts. 
 
Genotyping PCR     
For routine genotyping, DNA was extracted from lysed ear notch / tissue samples using tail 
lysis buffer supplemented with proteinase K as described (20), and end-point PCR performed 
with specific primer pairs (Supplemental Table 3) before resolving by agarose gel 
electrophoresis. Routine genotyping was subsequently outsourced to Transnetyx (Cordova, 
TN, USA) for automated analysis. 
End-point PCR was also used to confirm cardiomyocyte-specific deletion of Il1a exon 
4 in whole heart tissue and fibroblast-specific deletion of Il1r1 exon 5 in cultured cardiac 
fibroblasts using specific primer sets (Supplemental Table 3).  
 
Experimental MI model 
A permanent LAD coronary artery ligation model of experimental MI was performed on 5% 
isoflurane-anaesthetized male mice (10-12 weeks of age), as we described previously (38). 
Following intubation, mice were ventilated at a tidal volume of 140 l and a respiratory rate 
of 120/min with 1.5% isoflurane and 100% oxygen. The LAD was ligated at the edge of the 
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left atrium using 8-0 prolene suture and occlusion confirmed by observing pallor of the 
anterior LV wall.  
For cardiomyocyte-targeted mice, LAD ligation was performed on Cre-positive 
(MIL1AKO) and Cre-negative (control) littermates. For fibroblast-targeted mice, LAD 
ligation was performed on Cre-positive (FIL1R1KO) and Cre-negative (control) littermates 
that had been injected with tamoxifen at 12 days of age. Sham operated animals (no 
tamoxifen treatment) underwent a similar surgical procedure without tying the ligature. In 
order to keep the number of animals used to a minimum, sham data was combined from the 
two different genotypes (Cre-positive and Cre-negative), which showed no differences in 
baseline phenotype.   
 
Measurement of cardiac function 
Physiological measurements of cardiac function were obtained by Millar conductance P-V 
catheter analysis, as we have described in full previously (20,39). The investigator 
performing the P-V measurements was blinded to the genotype of the animals. 
 
Histology 
Hearts were extracted at various time points and fixed in 4% paraformaldehyde before 
paraffin wax-embedding. Tissue sections (5 m) were stained as we described previously 
with Miller’s elastic van Gieson (MVG) stain (40) or with antibodies for tenascin-C (Santa 
Cruz Biotechnology sc-8694) (38). Composite tiled images were prepared from individual 
photomicrographs so that cross-sections through the whole heart could be observed.  
 
Real-time qRT-PCR 
RNA was purified from cells or snap-frozen heart tissue, and cDNA synthesis performed as 
described previously (20). Real-time qRT-PCR was undertaken using an ABI-7500 System 
with specific Taqman primer/probe sets (Applied Biosystems) for detecting Acta2 
(Mm00725412_s1), Col1a1 (Mm00801666_g1), Col3a1 (Mm01254476_m1), Gapdh 
(Mm99999915_g1), Il1a (Mm99999060_m1), Il1b (Mm00434228_m1), Il1r1 
(Mm01226961), Il6 (Mm00446190_m1), Mmp3 (Mm00440295_m1), Mmp9 
(Mm00442991_m1), Myh7 (Mm00600555_m1), Nppa (Mm01255747_g1), Postn 
(Mm01284919_m1), Tnc (Mm00495662_m1) and Tnfa (Mm00443258_m1). Data are 
expressed relative to Gapdh mRNA expression using the 2-ΔCT method. 
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Cardiac fibroblast culture 
Cardiac fibroblasts were cultured from mouse hearts by a collagenase digestion method, as 
we described previously (20,41). Experiments were performed in serum-free medium using 
early passage (P0 or P1) cells. 
 
Immunoblotting 
Immunoblotting was performed as described previously (42) using Cell Signaling 
Technology antibodies for phospho-p38 (#9211) and IκB- expression (#9242). β-actin 
expression (loading control) was detected with Abcam ab8226 antibody. Horseradish 
peroxidase-conjugated secondary antibodies and enhanced chemiluminescence detection 
reagent were from GE Healthcare. Blots were imaged using G:BOX gel doc system 
(Syngene) and band intensities quantified using GeneTools software (Syngene).    
 
Statistics 
Statistical analyses were conducted using GraphPad Prism 7.01 Software 
(www.graphpad.com). Unless stated otherwise, data are mean values ± SEM. Box plots 
illustrate median, 25th/75th percentiles and minimum/maximum. The n value represents the 
number of separate animals or the number of cell cultures from separate hearts (i.e. biological 
replicates). Data were analyzed by 2-tailed t-test, 2-way ANOVA (with Bonferroni post hoc) 
or 1-way ANOVA (with Tukey post hoc), as appropriate. A P value less than 0.05 was 
considered significant.  
 
Study approval 
All animal procedures were carried out in accordance with the Animal Scientific Procedures 
Act (UK) 1986 under UK Home Office authorization following review by the University of 
Leeds Animal Welfare and Ethical Review Committee. 
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Figure 1. Creation, characterization and functional assessment of cardiomyocyte-
specific IL-1 knockout mouse line (MIL1AKO). (A) Generation of floxed interleukin-1 
(exon 4) mice: Il1afl/fl. Genetic targeting shows exon 4 flanked by loxP sites, positioned 
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upstream of a lacZ/Neo resistance cassette, which is excised upon Flp recombination, 
resulting in the generation of Il1afl/fl allele. Cre recombinase leads to exon 4 deletion, 
generating IL-1 knockout (KO) mice. (B) Genotyping showing exon 4 deletion of Il1a gene. 
Size markers (bp) are to the left. Upper panel: PCR analysis for Il1a exon 4 deletion (456 bp) 
in cardiac tissue from Cre-negative Il1afl/fl and Myh6-Cre-positive Il1afl/fl (MIL1AKO) mice. 
Lower panel: PCR analysis for exon 4 deletion (456 bp) in various tissues in Cre-positive 
MIL1AKO mice, confirming cardiac-specific deletion. See Supplemental Table 3 for primer 
details. (C) Timeline showing experimental myocardial infarction (MI) induced by ligation of 
the left anterior descending (LAD) coronary artery and time points for collection of RNA, 
histology and measurement of cardiac function by pressure-volume (P-V) conductance 
catheter. (D) qRT-PCR analysis of basal Il1a mRNA expression in hearts from control (Ctrl; 
Cre-negative Il1afl/fl) and MIL1AKO (MKO; Myh6-Cre-positive Il1afl/fl) mice. *P<0.05 for 
effect of KO (unpaired t-test, n=4). (E) P-V conductance catheter data. Sham = mixed 
genotypes (n=19); MI Ctrl = Cre-negative Il1afl/fl after MI (n=19); MI MKO = Myh6-Cre-
positive Il1afl/fl (MIL1AKO) after MI (n=17). ***P<0.05 versus sham; NS = not significant 
between the 2 MI groups (1-way ANOVA with Tukey post hoc). (F) qRT-PCR data showing 
relative mRNA levels of remodeling genes interleukin-1β (Il1b), tumor necrosis factor  
(Tnfa), interleukin-6 (Il6), matrix metalloproteinases 3 and 9 (Mmp3, Mmp9), tenascin C 
(Tnc), -smooth muscle actin (Acta2), periostin (Postn), collagen I1 (Col1a1) and collagen 
III1 (Col3a1). Sham = mixed genotypes (n=7); MI Ctrl = Cre-negative Il1afl/fl after MI 
(n=5); MI MKO = Myh6-Cre-positive Il1afl/fl (MIL1AKO) after MI (n=5). ***P<0.01, 
**P<0.01, *P<0.05 versus sham; NS = not significant between MI groups (1-way ANOVA 
with Tukey post hoc). 
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Figure 2. Effect of cardiomyocyte-specific IL-1 deletion on cardiac remodeling post-
MI. (A) Representative photographs of sham and myocardial infarction (MI) hearts at end of 
experimental period (4 weeks after surgery). Sham = mixed genotypes; MI Ctrl = Cre-
negative Il1afl/fl after MI; MI MIL1AKO = Myh6-Cre-positive Il1afl/fl after MI (n=5). Dashed 
line = infarcted area. (B) Representative photomicrographs of histological sections of hearts 
stained with Miller’s elastic van Gieson. Yellow stain = muscle, pink = collagen, purple = 
elastin. Scale bars: 700 m.  
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Figure 3. Effect of global IL-1R1 knockout on cardiac fibroblast responses to 
inflammatory cytokines. (A) qRT-PCR data showing basal interleukin-1 receptor 1 (Il1r1) 
mRNA levels in cardiac fibroblasts cultured from wild-type (+/+), IL-1R1 heterozygote (+/-) 
and IL-1R1 knockout (KO) (-/-) mice (all n=4). ***P<0.01, *P<0.05 versus wild-type (1-way 
ANOVA with Tukey post hoc). (B) Cardiac fibroblasts were exposed to vehicle control (‘C’), 
1 ng/ml interleukin-1 (IL1) or 10 ng/ml tumor necrosis factor  (TNF) for 30 min. 
Immunoblotting was used to measure activation of p38 MAP kinase (phosphorylation; p-p38) 
or activation of IκB- (proteasome-mediated degradation). β-actin = loading control. 
Numbers under blots represent densitometric analysis relative to β-actin and normalized to 
lane 1. Representative of 2 separate experiments. (C,D) Cardiac fibroblasts were treated with 
vehicle (open boxes) or 1 ng/ml IL-1 (closed boxes) for 6 h before measuring mRNA levels 
of interleukin-6 (Il6) and matrix metalloproteinases 3 and 9 (Mmp3, Mmp9) by qRT-PCR (C) 
and protein secretion by ELISA (D). (E) Cardiac fibroblasts were treated with vehicle (open 
boxes) or 10 ng/ml TNF (closed boxes) for 6 h before measuring Mmp9 mRNA levels by 
qRT-PCR. ***P<0.01, **P<0.01, *P<0.05, NS = not significant for effect of cytokine. 
###P<0.01, ##P<0.01, NS = not significant for effect of IL-1R1 KO (2-way ANOVA with 
Bonferroni post hoc). n=4 per genotype. 
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Figure 4. Effect of tamoxifen-induced fibroblast-specific IL-1R1 knockdown on cardiac 
fibroblast responses to IL-1. (A) Schematic showing loxP-targeted Cre-mediated deletion of 
exon 5 within the interleukin-1 receptor-1gene, Il1r1. (B-E) Fibroblast cultures were 
established from hearts of Cre-negative (Ctrl; n=7) and Cre-positive (fibroblast-specific 
interleukin-1 receptor 1 knockout [FIL1R1KO]; n=5) hemizygous Il1r1fl/- mice 6 weeks after 
tamoxifen injection. (B) qRT-PCR analysis of basal Il1r1 mRNA expression in cardiac 
fibroblasts from Ctrl and FIL1R1KO mice. **P<0.01 for effect of KO (unpaired t-test). (C) 
Cardiac fibroblasts with different genotypes were exposed to vehicle (control, C), interleukin-
1 (IL-1) or tumor necrosis factor  (TNF) for 30 min before immunoblotting to measure 
activation of p38 MAP kinase (phosphorylation; p-p38) or activation of IκB- (proteasome-
mediated degradation). β-actin = loading control. Plots to the right depict densitometric 
analysis relative to β-actin and normalized to lane 1 for control (open symbols) or IL-1 
treatment (closed symbols). n=2. (D,E) Cardiac fibroblasts were treated with vehicle (open 
boxes) or 1 ng/ml IL-1 (closed boxes) for 6 h before measuring mRNA levels of 
interleukin-6 (Il6) and matrix metalloproteinases 3 and 9 (Mmp3, Mmp9) by qRT-PCR (D), 
and IL-6 secretion by ELISA (E). ***P<0.001, **P<0.01, *P<0.05, NS = not significant for 
effect of IL-1; ##P<0.01, #P<0.05 for effect of IL-1R1 KO (2-way ANOVA with Bonferroni 
post hoc).  
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Figure 5. Effect of fibroblast-specific IL-1R1 deletion on cardiac function and 
remodeling genes 4 weeks post-MI. (A) Experimental timeline showing timing of tamoxifen 
injection and experimental myocardial infarction (MI) induced by ligation of the left anterior 
descending (LAD) coronary artery, as well as timings for histology, collection of RNA, and 
measurement of cardiac function by pressure-volume (P-V) conductance catheter. (B) P-V 
conductance catheter data. Sham = mixed genotypes, no tamoxifen treatment (n=18); MI Ctrl 
= tamoxifen-treated Cre-negative Il1r1fl/- after MI (n=11); MI FKO = tamoxifen-treated Cre-
positive Il1r1fl/- (FIL1R1KO; fibroblast-specific interleukin-1 receptor 1 knockout) after MI 
B.
A.                                                                     
C.
days                           weeks
0 +5                             +4  +6  
LAD
ligation
P-V
& mRNA
10-12 weeks
old
Histology
+ Tamoxifen
5 days
12 days
old
Histology
FIL1R1KO
Sham MI
Ctrl
MI
FKO
0
5000
10000
15000
20000
dPdt max
d
P
d
t 
m
a
x
 (
m
m
H
g
/s
e
c
)
*
Sham MI
Ctrl
MI
FKO
0
20
40
60
End Diastolic Volume
E
D
V
 (

l)
Sham MI
Ctrl
MI
FKO
0
20
40
60
80
100
Ejection Fraction
E
F
 (
%
) *
Sham MI
Ctrl
MI
FKO
0
10
20
30
40
End Systolic Volume
E
S
V
 (

l)
Sham MI
Ctrl
MI
FKO
0.0
0.2
0.4
0.6
0.8
1.0
Col1a1
%
 G
a
p
d
h
*
Sham MI
Ctrl
MI
FKO
0
5
10
15
Col3a1
%
 G
a
p
d
h
***
**
#
Sham MI
Ctrl
MI
FKO
0.00
0.05
0.10
0.15
Mmp3
%
 G
a
p
d
h
**
Sham MI
Ctrl
MI
FKO
0.00
0.01
0.02
0.03
0.04
Mmp9
%
 G
a
p
d
h
Sham MI
Ctrl
MI
FKO
0.00
0.05
0.10
0.15
0.20
0.25
Acta2
%
 G
a
p
d
h
Sham MI
Ctrl
MI
FKO
0
5
10
15
20
Nppa
%
 G
a
p
d
h
Sham MI
Ctrl
MI
FKO
0
2
4
6
8
Myh7
%
 G
a
p
d
h
Sham MI
Ctrl
MI
FKO
0.0
0.1
0.2
0.3
0.4
0.5
Il6
%
 G
a
p
d
h
Sham MI
Ctrl
MI
FKO
0.0
0.1
0.2
0.3
0.4
Tnc
%
 G
a
p
d
h
*
26 
 
(n=11). *P<0.05 versus sham. (C) qRT-PCR data showing relative mRNA levels of 
remodeling genes collagen I1 (Col1a1), collagen III1 (Col3a1), matrix metalloproteinases 
3 and 9 (Mmp3, Mmp9), -smooth muscle actin (Acta2), tenascin C (Tnc), interleukin-6 (Il6), 
β-myosin heavy chain (Myh7) and atrial natriuretic factor (Nppa). Sham = mixed genotypes, 
no tamoxifen treatment (n=8); MI Ctrl = tamoxifen-treated Cre-negative mice after MI (n=8); 
MI FKO = tamoxifen-treated FIL1R1KO mice after MI (n=8). ***P<0.01, **P<0.01, 
*P<0.05 versus sham; #P<0.05 versus MI Ctrl (1-way ANOVA with Tukey post hoc).  
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Figure 6. Effect of fibroblast specific IL-R1 deletion on histological markers of cardiac 
remodelling 5 days post-MI. Representative photomicrographs of adjacent histological 
sections from Control and F1L1RKO (fibroblast-specific interleukin-1 receptor 1 knock out) 
hearts. Left panels: H&E staining showing inflammatory infiltrates and interstitial cells in the 
infarct zone. Middle panels: Miller’s elastic van Gieson (MVG) staining showing elastin 
(blue) and collagen (pink) staining; muscle tissue is stained yellow. Right panels: Tenascin C 
staining (brown). Scale bars: 500µm. 
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Figure 7. Effect of fibroblast specific IL-R1 deletion on histological markers of cardiac 
remodelling 6 weeks post-MI. Representative photomicrographs of adjacent histological 
sections from Control and F1L1RKO (fibroblast-specific interleukin-1 receptor 1 knock out) 
hearts. Left panels: H&E staining showing inflammatory infiltrates and interstitial cells in the 
infarct zone. Middle panels: Miller’s elastic van Gieson (MVG) staining showing elastin 
(blue) and collagen (pink) staining; muscle tissue is stained yellow. The area of ventricular 
thinning is indicated with an arrow head. Right panels: Tenascin C staining (brown). Scale 
bars: 500µm. 
